SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D.C. 20549

                                   FORM 10-Q

                  QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                    For the quarter ended December 31, 2009

                         Commission File Number 0-10683

                                 HYDROMER, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)
     New Jersey                                                 22-2303576
----------------------                                 -------------------------
(State of incorporation)                                   (I.R.S. Employer
                                                           Identification No.)

35 Industrial Pkwy, Branchburg, New Jersey                      08876-3424
------------------------------------------             -------------------------
  (Address of principal executive offices)                      (Zip Code)

Registrant's telephone number, including area code:         (908) 722-5000
                                                       -------------------------

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

                         Common Stock Without Par Value
                         ------------------------------
                                (Title of class)

   Indicate  by  check  mark  whether  the  registrant (1) has filed all reports
required  to  be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X]   No  [ ]

   Indicate  by  check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
        Large accelerated filer [ ]     Accelerated filer [ ]
        Non-accelerated filer [ ]       Smaller reporting company [X]

   Indicate  by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).   Yes  [ ]   No  [X]



         Class                     Outstanding at December 31, 2009
         -----                     --------------------------------
        Common                                 4,772,318























<PAGE>
                                 HYDROMER, INC.


                               INDEX TO FORM 10-Q
                               December 31, 2009

                                                                        Page No.
Part I  -  Financial Information

      # 1 Consolidated Financial Statements

             Balance Sheets - December 31, 2009 & June 30, 2009             2

             Statements of Operations for the three months and six
                months ended December 31, 2009 and 2008                     3

             Statements of Cash Flows for the six months ended
                December 31, 2009 and 2008                                  4

             Notes to Financial Statements                                  5

      # 2  Management's Discussion and Analysis of the Financial
                Condition and Results of Operations                         6

      # 3  Controls and Procedures                                          8


Part II  -  Other Information

      # 1  Legal Proceedings                                              N/A

      # 2  Change in Securities                                           N/A

      # 3  Default of  Senior Securities                                  N/A

      # 4  Submission of Motion to Vote of Security Holders               N/A

      # 5  Other Information                                              N/A

      # 6  Exhibits                                                         9


                                 EXHIBIT INDEX

Exhibit No.   Description of Exhibit
-----------   ----------------------
31.1          SEC Section 302 Certification - CEO certification            11
31.2          SEC Section 302 Certification - CFO certification            12

32.1          Certification of Manfred F. Dyck, Chief Executive Officer,
                      pursuant to 18 U.S.C. Section 1350                   13

32.2          Certification of Robert Y. Lee, Chief Financial Officer,
                      pursuant to 18 U.S.C. Section 1350                   13























                                       1
<PAGE>
PART I - CONSOLIDATED FINANCIAL STATEMENTS
ITEM # 1

<TABLE>

                                          HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                                 CONSOLIDATED BALANCE SHEETS

<S>                                                                            <C>                 <C>
                                                                               December 31,        June 30,

                                                                                   2009              2009

                                                                                UNAUDITED           AUDITED
      ASSETS
      Current Assets:
          Cash and cash equivalents                                          $     1,274,903   $     1,585,765
          Short-term investments                                                     440,000           450,000
          Trade receivables less allowance for doubtful accounts of
               $40,120 and $57,741 as of December 31, 2009 and June 30,
               2009, respectively                                                    708,896         1,058,978
          Inventory                                                                  257,744           615,849
          Prepaid expenses                                                           149,736           204,280
          Deferred tax asset                                                           8,976             8,976
          Other                                                                      405,953             8,968
      ----------------------------------------------------------------------------------------------------------
      Total Current Assets                                                         3,246,208         3,932,816
      ----------------------------------------------------------------------------------------------------------

      Property and equipment, net                                                  2,988,912         3,135,017
      Deferred tax asset, non-current                                                748,095           521,986
      Intangible assets, net                                                         788,991           740,426
      ----------------------------------------------------------------------------------------------------------
      Total Assets                                                           $     7,772,206   $     8,330,245
      ----------------------------------------------------------------------------------------------------------

      LIABILITIES AND STOCKHOLDERS' EQUITY
      Current Liabilities:
          Accounts payable                                                   $       384,395   $       380,838
          Accrued expenses                                                           221,331           341,088
          Current portion of capital lease                                            15,402            14,473
          Current portion of deferred revenue                                         80,758            82,132
          Current portion of mortgage payable                                         47,176            45,696
          Income tax payable                                                           2,080            75,891
      ----------------------------------------------------------------------------------------------------------
      Total Current Liabilities                                                      751,142           940,118
      ----------------------------------------------------------------------------------------------------------
      Deferred tax liability                                                         284,503           285,858
      Long-term portion of capital lease                                              42,952            50,258
      Long-term portion of deferred revenue                                          174,904           161,019
      Long-term portion of mortgage payable                                        2,795,293         2,820,055
      ----------------------------------------------------------------------------------------------------------
      Total Liabilities                                                            4,048,794         4,257,308
      ----------------------------------------------------------------------------------------------------------

      Stockholders' Equity
          Preferred stock - no par value, authorized 1,000,000 shares, no
             shares issued and outstanding                                                -                 -
          Common stock - no par value, authorized 15,000,000 shares;
               4,783,235 shares issued and 4,772,318 shares outstanding as
               of December 31, 2009 and June 30, 2009                              3,721,815         3,721,815
          Contributed capital                                                        633,150           633,150
          Accumulated deficit                                                       (625,413)         (275,888)
          Treasury stock, 10,917 common shares at cost                                (6,140)           (6,140)
      ----------------------------------------------------------------------------------------------------------
      Total Stockholders' Equity                                                   3,723,412         4,072,937
      ----------------------------------------------------------------------------------------------------------
      Total Liabilities and Stockholders' Equity                             $     7,772,206   $     8,330,245
      ----------------------------------------------------------------------------------------------------------
</TABLE>







                                       2
<PAGE>

<TABLE>

                                          HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                            CONSOLIDATED STATEMENTS OF OPERATIONS

<S>                                                           <C>              <C>             <C>              <C>
                                                               Three Months Ended                 Six months Ended
                                                                  December 31,                      December 31,
                                                               2009            2008             2009             2008
                                                            UNAUDITED        UNAUDITED          UNAUDITED       UNAUDITED
---------------------------------------------------------  -----------------------------    ------------------------------
REVENUES
    Sale of products                                     $     829,402    $  1,235,533    $    2,011,106   $   2,353,601
    Service revenues                                           359,491         497,750           659,283       1,012,076
    Royalties and Contract Revenues                            227,221         416,418           455,296         819,993
                                                           -------------    ------------    --------------   -------------

         TOTAL REVENUES                                      1,416,114       2,149,701         3,125,685       4,185,670
---------------------------------------------------------  -----------------------------    ------------------------------

EXPENSES
   Cost of Sales                                               627,263         854,238         1,467,457       1,646,556
   Operating Expenses                                        1,221,493       1,191,534         2,487,853       2,344,548
   Other Expenses                                               30,024          46,916            81,638          87,567
   Gain from Sale of Assets                                   (335,629)             -           (335,629)             -
   (Benefit from) Provision for Income Taxes                   (49,900)         20,320          (226,109)         28,000
                                                           -------------    ------------    --------------   -------------

         TOTAL EXPENSES                                      1,493,251       2,113,008         3,475,210       4,106,671
---------------------------------------------------------  -----------------------------    ------------------------------

         NET (LOSS) INCOME                               $     (77,137)   $     36,693    $     (349,525)  $      78,999
---------------------------------------------------------  -----------------------------    ------------------------------

         (Loss) Earnings Per Common Share                $       (0.02)   $       0.01    $        (0.07)  $        0.02

Weighted Average Number of
         Common Shares Outstanding                            4,772,318       4,772,318         4,772,318       4,772,318
         Common Shares Outstanding assuming dilution                          4,773,655                         4,772,986


                    There  was  no  impact  to  earnings per share from dilutive securities.
                      For  the  2009 period, the resultant would have been anti-dilutive.
</TABLE>
































                                       3
<PAGE>

<TABLE>
                                          HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                            CONSOLIDATED STATEMENTS OF CASH FLOWS

<S>                                                                                <C>             <C>
                                                                                        Six months Ended
                                                                                          December 31,
                                                                                     2009            2008
                                                                                   UNAUDITED      UNAUDITED
         -----------------------------------------------------------------------------------------------------
         CASH FLOWS FROM OPERATING ACTIVITIES:
             Net (Loss) Income                                                 $    (349,525)  $      78,999
        Adjustments to reconcile net (loss) income to net cash

             Provided by (Used for) operating activities
                Gain on Sale of Product Lines                                       (335,629)             -
                Depreciation and amortization                                        220,542         207,339
                Charge-off of Patent Costs                                                -           63,242
                Deferred income taxes                                               (227,464)         24,052
                Changes in Assets and Liabilities:
                  Trade receivables                                                  350,082          63,067
                  Inventory                                                           61,612         162,472
                  Prepaid expenses                                                    54,544           1,789
                  Other assets                                                       (11,706)         (2,144)
                  Accounts payable and accrued liabilities                          (116,200)       (138,683)
                  Deferred income                                                     12,511          25,925
                  Income taxes payable                                               (73,811)          2,908
         -----------------------------------------------------------------------------------------------------

                      Net Cash (Used for) Provided by Operating Activities          (415,044)        488,966

         -----------------------------------------------------------------------------------------------------

         CASH FLOWS FROM INVESTING ACTIVITIES:
             Cash purchases of property and equipment                               (126,436)        (92,292)
             Cash payments on patents and trademarks                                (156,100)       (185,802)
             Redemption of matured short-term investments                            260,000               -
             Cash purchases of short-term investments                               (250,000)              -
             Proceeds Received from the sale of Product Lines                        400,000
         -----------------------------------------------------------------------------------------------------

                      Net Cash Provided by (Used for) Investing Activities           127,464        (278,094)

         -----------------------------------------------------------------------------------------------------
         CASH FLOWS FROM FINANCING ACTIVITIES:
             Net repayments toward Line of Credit                                       -           (289,973)
             Proceeds from long-term borrowings                                         -          2,900,000
             Repayment of long-term borrowings                                       (23,282)     (1,889,257)
         -----------------------------------------------------------------------------------------------------

                      Net Cash (Used for) Provided by Financing Activities           (23,282)        720,770

         -----------------------------------------------------------------------------------------------------
         NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS:                      (310,862)        931,642
         Cash and Cash Equivalents at Beginning of Period                          1,585,765         108,403
         -----------------------------------------------------------------------------------------------------

         Cash and Cash Equivalents at End of Period                            $   1,274,903   $   1,040,045
         -----------------------------------------------------------------------------------------------------

         Non-Cash Investing and Financing Activities:
             Note Receivable in exchange for Sale of Product Lines             $     400,000

</TABLE>












                                       4
<PAGE>

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY

                   Notes to Consolidated Financial Statements

In  the  opinion  of management, the accompanying unaudited financial statements
include  all adjustments (consisting of only normal adjustments) necessary for a
fair   presentation   of   the   results   for   the  interim  periods.  Certain
reclassifications  have  been  made  to  the  previous year's results to present
comparable financial statements.

Significant Events:
-------------------
On  November  25, 2009, the Company's wholly owned subsidiary, Biosearch Medical
Products,  Inc.  ("BMPI")  sold  its  Private  Label  Jejunostomy  Catheter  and
Nasogastric   Feeding   Catheter  business  to  Forefront  Medical  Technologies
("Forefront"),  a  wholly  owned subsidiary of Vicplas International Limited - a
company  registered  in the Republic of Singapore, for $800,000 in cash. Half of
the  sales proceeds was received upon closing with the balance due in early 2010
when  the  transition  is  complete. This sale included inventory and equipment
related  to  that business and also calls for the assignment of certain customer
supply  agreements  to  Forefront  and  a  three  year  non-compete provision. A
separate  supply  agreement for Hydromer(R) hydrophilic coating solution used on
those  products  was  also  entered  between  the  parties.  BMPI  will continue
manufacturing  the  products,  at an agreed upon transfer price, until Forefront
completes  the  transition which is expected to occur on or about February 28,
2010 in accordance with the sales agreement.  Accordingly, this transaction does
not meet the criteria  of  Discontinued  Operations  of  Financial Accounting
Standards Board ("FASB")  Accounting  Standards  Codification ("ASC") paragraphs
205-20. These product lines  sold  were  part of the "Medical Products" segment
(see following Segment Reporting section).

New Accounting Pronouncements
-----------------------------
   In October 2009, the  FASB issued ASU 2009-13, Multiple-Deliverable Revenue
Arrangements, (amendments to FASB ASC Topic 605, Revenue Recognition)
("ASU 2009-13"). ASU 2009-13 requires entities to allocate revenue in an
arrangement using estimated selling prices of the delivered goods and services
based on a selling price hierarchy. The amendments eliminate the residual method
of revenue allocation and require revenue to be allocated using the relative
selling price method. ASU 2009-13 is effective on a prospective basis for
revenue arrangements entered into or materially modified in fiscal years
beginning on or after June 15, 2010, with early adoption permitted. ASU 2009-13
will become effective for the Company with its fiscal year beginning July 1,
2010 and the Company believes that there will not be a material impact on its
results of operations or financial condition as a result of adoption of this
Update.

       In January 2010, the FASB issued ASU 2010-06, Fair Value Measurements and
Disclosures,(amendments to FASB ASC Topic 820, Fair Value Measurements and
Disclosures) ("ASU 2010-06").  ASU 2010-06 requires entities to disclose
separately the amounts of significant transfers in and out of Level 1 and Level
2  fair value measurements along with the reasons for such transfers.  Entities
should  also present separate information about purchases, sales, issuances and
settlement activity in Level 3 fair value measurements. The Update requires
entities to provide fair value measurement disclosures for each class of assets
and  liabilities  and  disclosures about inputs and valuation techniques.  The
new disclosures and clarifications of existing disclosures are effective for
interim and annual reporting periods beginning after December 15, 2009 except
for the disclosures pertaining to Level 3 fair value measurements. Those
disclosures are effective  for interim and fiscal years beginning after
December 15, 2010.  This Update will become effective for the Company with
its interim period beginning January 1, 2010 and the Company believes that there
will not be a material impact on its results of operations or financial
condition as a result of adoption of this Update.

FAIR VALUE
----------

In accordance with FASB ASC 820, "Fair Value Measurements and Disclosures", the
following table represents the Company's fair value hierarchy for its financial
assets and liabilities measured at fair value on a recurring basis as of
December 31, 2009:




                                       5
<PAGE>
        ---------------- ------------ ----------- ----------- ------------
                           Level 1     Level 2     Level 3       Total
                           -------     -------     -------       -----
        ASSETS
            Investments  $  440,000                           $  440,000
                            -------                              -------
        Total Assets     $  440,000         -           -     $  440,000
                            =======                              =======

        LIABILITIES - n/a         -         -           -             -
        ---------------- ------------ ----------- ----------- ------------

Some  of the Company's financial instruments are not measured at fair value on a
recurring  basis  but are recorded at amounts that approximate fair value due to
their   liquid  or  short-term  nature,  such  as  cash  and  cash  equivalents,
receivables  and  payables. The carrying amount of the Company's note obligation
approximates  its  fair value, as the terms of the note is consistent with terms
available in the market for instruments with similar risk.

Segment Reporting:
------------------
The  Company  operates  two primary business segments. The Company evaluates the
segments  by  revenues,  total  expenses  and  earnings  before taxes. Corporate
Overhead  is  excluded  from  the  business  segments  as  to  not  distort  the
contribution  of  each  segment.  These segments are the lowest levels for which
identifiable  cash  flows  are  largely  independent  of the cash flows of other
assets and liabilities.

The results for the six months ended December 31, by segment are:

<TABLE>
<S>                                                  <C>            <C>                 <C>            <C>
                                                      Polymer          Medical       Corporate
                                                      Research         Products      Overhead          Total
         2009 (excludes the Sale of Product Lines)
         Revenues                                  $   1,884,565   $     1,241,120                $    3,125,685
         Expenses                                     (1,925,793)       (1,315,354)  $ (795,801)      (4,036,948)
                                                   --------------  ----------------  -----------  ---------------
              Pre-tax Loss                         $     (41,228)  $       (74,234)   $ (795,801)  $    (911,263)
                                                   ==============  ================  ===========  ===============


         ---------------------------------------- ---------------- ----------------- -------------- ----------------
         2008
         Revenues                                  $    2,419,215   $    1,766,455                   $    4,185,670
         Expenses                                      (1,748,483)      (1,542,106)  $    (788,082)      (4,078,671)
                                                   ---------------  ---------------  --------------  ---------------
              Pre-tax Income (Loss)                $      670,732   $      224,349   $    (788,082)  $      106,999
                                                   ===============  ===============  ==============  ===============
</TABLE>


Geographic revenues were as follows for the six months ended December 31,

                                                             2009      2008
                                                             ----      ----
                                 Domestic                     73%       83%
                                 Foreign                      27%       17%


ITEM #2

                  MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                 ---------------------------------------------

Results of Operations
---------------------

The  Company's revenues for the quarter ended December 31, 2009 were $1,416,114,
34.1%  lower  than the $2,149,701 for the same period the previous year. For the
six  month  period ended December 31, 2009, revenues were $3,125,685 as compared
with  $4,185,670 the corresponding period a year ago; $1,059,985 or 25.3% lower.
Revenues  are  comprised  of  the  sale of Products and Services and Royalty and
Contract payments.


                                       6
<PAGE>
      Product  sales  were  $829,402  for the quarter ended December 31, 2009 as
      compared  to  $1,235,533  for  the same period the year before, a $406,131
      (32.9%)  decrease;  lower  due to impact to sales from product lines being
      sold  to  Merit  Medical  Systems,  Inc.  ("Merit")  in February 2009. (We
      continued  to  manufacture for Merit under a transfer agreement at a lower
      price  until October 2009 at which point Merit was able to manufacture the
      products  themselves).  For  the  six  month  period,  product  sales were
      $2,011,106  for  the  current  fiscal  year as compared with $2,353,601 or
      $342,945 (14.6%) lower than the same period the year before.

      Services  revenues  for  the  three  months  ended  December  31, 2009 was
      $359,491  or  $138,259  lower  (27.8%) than the $497,750 the corresponding
      period  the  year  before.  Services  revenues  for  the  six months ended
      December  31,  2009  was  $659,283  or  $352,793  (34.9%)  lower  than the
      $1,012,076  the  year  before.  Included  in the prior year's revenues was
      $145,000  in  R&D services in which the project was completed in the prior
      fiscal year. The conversion of a customer from contract coatings servicing
      to  product sales accounted for $303,385 of lower services revenues during
      the six month period.

      Royalty  and Contract revenues include royalties received and the periodic
      recurring  payments  from  license,  stand  still and other agreements for
      other than product and services. Included in Royalty and Contract revenues
      are revenues from support and supply agreements. Some of the royalties and
      support  fees  are  based on the net sales of the final item (to which the
      Hydromer technology is applied to) and are subject to the reporting of our
      customers.  For  the quarter ended December 31, 2009, Royalty and Contract
      revenues  were  $227,221, compared to $416,418 the same period a year ago.
      For  the  six  month  period, Royalty and Contract revenues were $455,296,
      compared  to  $819,993  for  the  2009 and 2008 periods, respectively. The
      cancellation  of  a  supply  and  support  agreement of $100,000 per month
      effective  January 1, 2009, replaced by a similar agreement at $35,000 per
      month, was the primary factor behind the difference.

      As  of  December  31,  2009,  our  open sales order book was approximately
      $817,000.  Although  some  of  the  sales orders can be cancelled prior to
      production,   the   Company   is   of  the  opinion  that  no  substantial
      cancellations  will  occur.  This  value  is  lower than previous reported
      periods  due  to  the sale of product lines to Merit and the conclusion of
      the production transfer period.

Total  Expenses  for  the  quarter  ended  December  31, 2009 were $1,493,251 as
compared  with  $2,113,008 the year before, a 29.3% decrease. For the six months
ended  December  31,  2008,  Total  Expenses  were  $3,475,210  as compared with
$4,106,671 the same period the year before, lower by 15.4%. Reducing this year's
expenses was the gain from the sale of product lines of $335,629.

      For  the quarter ended December 31, 2009, the Company's Cost of Goods Sold
      was  $627,263 as compared with $854,238 the year prior, lower by 26.6%. On
      a year-to-date basis, Cost of Goods Sold for fiscal 2009 (six months ended
      December  31,  2009)  was $1,467,457 as compared with $1,646,556 in fiscal
      2008,  or $179,099 (10.9% lower). Lower product sales, including that from
      the  sale  of product lines to Merit in February 2009, resulted in a lower
      Cost of Goods Sold.

      Operating expenses were $1,221,493 for the quarter ended December 31, 2009
      as  compared  with $1,191,534 the year before, up $29,959 or 2.5%. For the
      six  months ended December 31, 2009, Operating Expenses were $2,487,853 as
      up  $143,305  or  6.1%  from  the  $2,344,548 for the same period the year
      before.  The  increased  international  focus  in our T-HEXX Animal Health
      business,   including   a   dedicated  product  manager,  added  tradeshow
      promotions  and  marketing expenses resulted in $84,432 in higher costs in
      the current period. One time legal fees of $43,367 relating to the freedom
      to  market clearance review was incurred during the six month period. Such
      legal  fees allows for a new Hydrogel product launch with legal clearance.
      In  addition,  this  year  to  date  includes  $22,804 was spent on animal
      clinical  studies  on  our  soon  to  be  launched  DragonhydeTM Hoof Bath
      concentrate.  There has been highly favorable interest of our non-heavy
      metal/non-formalin  hoof bath product which we expect market launch in
      early 2010.  All  of the incremental spends this period are directly in
      relation towards future revenue sources.

      Interest  expense,  interest income and other income are included in Other
      Expenses.  Interest expense for the six months ended December 31, 2009 and
      December 31, 2008 were $103,595 and $100,005, respectively.


                                       7
<PAGE>
A  net  loss  of  $77,137  ($0.02  per  share) is reported for the quarter ended
December  31,  2009  as  compared to net income of $36,693 ($0.01 per share) the
year  before. For the six months ended December 31, 2009, a net loss of $349,525
($0.07 per share) compares against net income of $78,999 ($0.02 per share) for
the same period year before, a swing of $428,524.

      The  cancellation  and  subsequent  entering  of a lower valued supply and
      support  agreement  impacted operating income by $390,000 as compared with
      the prior year. The transfer price agreement with Merit impacted operating
      income by another $262,316. An income tax benefit of $176,209 was recorded
      for the six month period.

      Re-investment   expenditures  of  Research  and  Development  and  patents
      expenditures   accounted  for  approximately  $436,870  or  20.8%  of  the
      operating expenses.

Financial Condition

Working  capital  decreased  $497,631  during  the six months ended December 31,
2009.

Net  operating  activities  used  $415,044  during  the  six  month period ended
December 31, 2009.

      The net loss, as adjusted for non-cash expenses and less the gain from the
      sale   of   product  lines,  used  $692,076  in  cash.  Trade  receivables
      collections  provided  for  $350,082 in cash. Income taxes paid during the
      quarter was $73,811.

Investing  activities  provided  $127,464  and financing activities used $23,282
during the six months ended December 31, 2009.

      Investing  activities  for the six months ended December 31, 2009 included
      $126,436  for  capital  expenditures  and  $156,100  towards the Company's
      patent  estate.  $260,000  in short-term investments matured with $250,000
      being reinvested. $400,000 in cash was received, with another $400,000 due
      in  early 2010 from the sale of product lines. Under financing activities,
      the  principal  portion of debt servicing of the mortgage utilized $23,282
      in cash.

As  previously  reported, until replacement income is achieved, the cancellation
of  the  $100,000 per month Supply and Support Agreement and the sale of product
lines  to  Merit,  with  the  sales proceeds representing the future cash flows,
pushes  the  Company  into  an  operating loss position for the near future. The
timing    of   new   revenues,   including   that   from   its   anti-microbial,
anti-thrombogenic and cell mitosis technologies and new T-HEXX product lines and
broaden  T-HEXX  market  penetration,  are  in  varying  stages,  though  it  is
management's  expectations  that anything of significance, in the aggregate, are
at least a year away. The T-HEXX Dragonhyde Hoof Care product has been very well
received  and  we  expect sales to begin in early 2010. The Company has a strong
balance sheet to meet its required debt servicing.

ITEM # 3

Disclosure Controls and Procedures
----------------------------------

   As of the period covered by this  report, the Company carried out an
evaluation, under the supervision and with the participation of our management,
including the Chief  Executive Officer and President and the Chief Financial
Officer, of the effectiveness of the design and operation of the disclosure
controls and procedures.

    Based upon this evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that, our disclosure controls and procedures were effective
and that there were no changes to our Company's internal control over financial
reporting  that  have materially affected, or is reasonably likely to materially
affect the Company's internal control over financial reporting during the period
covered by the Company's quarterly report.

PART II - OTHER INFORMATION

   The Company operates entirely from its sole location at 35 Industrial Parkway
in  Branchburg, New Jersey, an owned facility secured by a mortgage through a
bank.


                                       8
<PAGE>
   The existing facility will be adequate for the Company's operations for the
foreseeable future.

ITEM # 6. Exhibits

       Exhibit No.    Description
       -----------    -----------
       31.1           Rule 13a-14(a) Certification of Chief Executive Officer
                        and President
       31.2           Rule  13a-14(a) Certification of Vice President of Finance
                        and Chief Financial  Officer
       32.1           Section 1350 Certification of Chief Executive Officer and
                        Chairman, President
       32.2           Section 1350 Certification of Chief Financial Officer and
                        Vice President of Finance






























































                                       9
<PAGE>
                                   SIGNATURES



Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on his behalf by the
undersigned thereunto duly authorized.

                                                        HYDROMER, INC.
                                                        /s/ Robert Y. Lee,VP
                                                        Robert Y. Lee
                                                        Chief Financial Officer



DATE: February 11, 2010





























































                                       10
<PAGE>
                                  EXHIBIT 31.1

I, Manfred F. Dyck, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
   statement  of a material fact or omit to state a material fact necessary
   to  make  the statements made, in light of the circumstances under which
   such  statements  were  made,  not misleading with respect to the period
   covered by this quarterly report;

3. Based  on  my  knowledge,  the financial statements, and other financial
   information  included  in  this  quarterly report, fairly present in all
   material  respects  the  financial  condition, results of operations and
   cash  flows  of  the registrant as of, and for, the periods presented in
   this quarterly report;

4. The  registrant's  other  certifying officer, Mr. Robert Y. Lee and I am
   responsible  for  establishing  and  maintaining disclosure controls and
   procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
   and  internal  control  over financial reporting (as defined in Exchange
   Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5. The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
   disclosed,  based  on  our  most  recent evaluation, to the registrant's
   auditors  and the audit committee of registrant's board of directors (or
   persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6. The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
   indicated  in  this  quarterly  report  whether  there  were significant
   changes   in   internal   controls   or  in  other  factors  that  could
   significantly  affect  internal  controls  subsequent to the date of our
   most  recent evaluation, including any corrective actions with regard to
   significant deficiencies and material weaknesses.

Date: February 11, 2010

/s/ Manfred F. Dyck
------------------------------------------
Manfred F. Dyck, President and CEO
                                       11
<PAGE>
                                  EXHIBIT 31.2

I, Robert Y. Lee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
   statement  of a material fact or omit to state a material fact necessary
   to  make  the statements made, in light of the circumstances under which
   such  statements  were  made,  not misleading with respect to the period
   covered by this quarterly report;

3. Based  on  my  knowledge,  the financial statements, and other financial
   information  included  in  this  quarterly report, fairly present in all
   material  respects  the  financial  condition, results of operations and
   cash  flows  of  the registrant as of, and for, the periods presented in
   this quarterly report;

4. The  registrant's other certifying officer, Mr. Manfred F. Dyck and I am
   responsible  for  establishing  and  maintaining disclosure controls and
   procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
   and  internal  control  over financial reporting (as defined in Exchange
   Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5. The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
   have disclosed, based on our most recent evaluation, to the registrant's
   auditors  and the audit committee of registrant's board of directors (or
   persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6. The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
   have  indicated  in this quarterly report whether there were significant
   changes   in   internal   controls   or  in  other  factors  that  could
   significantly  affect  internal  controls  subsequent to the date of our
   most  recent evaluation, including any corrective actions with regard to
   significant deficiencies and material weaknesses.

Date: February 11, 2010

Robert Y. Lee,VP
------------------------------------------
Robert Y. Lee, Vice President of Finance and CFO
                                       12
<PAGE>

                                  EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,

                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Manfred F. Dyck, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2009
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and that information contained in such report fairly
presents in all material respects the financial condition and results of
operations of Hydromer, Inc.

Date: February 11, 2010                 By: /s/ Manfred F. Dyck
                                           -------------------------------------
                                                Manfred F. Dyck
                                                Chairman, President and
                                                Chief Executive Officer


--------------------------------------------------------------------------------


                                  EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,

                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Robert  Y.  Lee,  certify,  pursuant  to  18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Hydromer, Inc. on Form 10-Q for the six months ended December 31, 2009
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: February 11, 2010                 By: /s/ Robert Y. Lee,VP
                                           -------------------------------------
                                                Robert Y. Lee
                                                Chief Financial Officer
                                                and Vice President of Finance


























                                       13